Investors | Xemperia SA

Investors

XEMPERIA is seeking investors interested in joining its promising journey in the development of cutting-edge diagnostic technologies.

It represents an attractive opportunity for investors aiming to substantially grow their capital.

XEMPERIA is a young start-up that already owns concrete, patented innovations with strong potential to become products in rapidly expanding markets.

Market Outlook

The global breast cancer diagnostics market is expected to record a CAGR of 7.5% from 2024 to 2033. In 2024, the market size is projected to reach USD 4.7 billion, and by 2033, it is anticipated to reach USD 11.3 billion (Itani, M. M. et al., A Signature of Four Circulating microRNAs as Potential Biomarkers for Diagnosing Early-Stage Breast Cancer, Int J Mol Sci, 22, 6121–2021).

The global liquid biopsy market was valued at USD 10.85 billion in 2023 and is expected to reach USD 32.54 billion by 2033 (CAGR: 11.61%; Madhavan, D. et al., Circulating miRNAs with Prognostic Value in Metastatic Breast Cancer and for Early Detection of Metastasis, Carcinogenesis, 37, 461–470–2016).

The breast cancer liquid biopsy market is projected to grow at a CAGR of 8.5% from 2025 to 2030 (Breast Cancer Liquid Biopsy Market Size, Share & Trends Analysis Report, 2025–2030).

The global miRNA market is forecasted to grow at a CAGR between 13% and 20%, reaching USD 7.7 billion by 2032.

Technology and Adaptability

XEMPERIA’s patented technologies were originally developed for the early detection of breast cancer, but they can be adapted for the early detection of other types of cancer as well.

Disclaimer

Naturally, any investment in a start-up – XEMPERIA included – carries significant risk, including the potential loss of the entire capital invested. Nothing on this website should be construed as investment advice.

Any investor in our project must be a financial professional or be advised by one. Accordingly, XEMPERIA assumes no responsibility for any negative performance resulting from an investor’s decision.

Interested in knowing more?